Skip to search formSkip to main contentSkip to account menu

carfilzomib 60 MG Injection [Kyprolis]

Known as: CARFILZOMIB 60 mg in 30 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [KYPROLIS], Kyprolis 60 MG Injection 
National Institutes of Health

Related topics

Related topics

8 relations
Citric Acid, AnhydrousInjectionKyprolisSodium Hydroxide

Broader (1)

carfilzomib Injection [Kyprolis]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Polymeric micelles loaded with carfilzomib increase tolerability in a humanized bone marrow-like scaffold mouse model
2019
2019
Apremilast ameliorates carfilzomib‐induced pulmonary inflammation and vascular injuries
2019
2019
High Effectiveness in Actions of Carfilzomib on Delayed-Rectifier K+ Current and on Spontaneous Action Potentials
Carfilzomib (CFZ, Kyprolis®) is widely recognized as an irreversible inhibitor of proteasome activity; however, its actions on… 
2017
2017
Carfilzomib (Kyprolis°) in multiple myeloma.
  • Prescrire international
  • 2017
  • Corpus ID: 73444034
Review
2016
Review
2016
Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma
Carfilzomib (Kyprolis®) is a proteasome inhibitor that binds selectively and irreversibly to the 20S proteasome (the proteolytic… 
2016
2016
Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death*
Multiple myeloma is an aggressive hematopoietic cancer of plasma cells. The recent emergence of three effective FDA-approved… 
2015
2015
Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®), and dexamethasone (DEX) (KRd) combined with autologous stem cell transplant (ASCT) shows improved efficacy compared with KRd without ASCT…
2015
2015
Carfilzomib (Kyprolis®) for patients with relapsed multiple myeloma who have received one to three prior lines of therapy
Carfilzomib (Kyprolis®) is a proteasome inhibitor, indicated in patients with multiple myeloma who have received one to three… 
Review
2014
Review
2014
Applied techniques for mining natural proteasome inhibitors.
2013
2013
Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma
ABSTRACT Carfilzomib (Kyprolis®), a second generation proteasome inhibitor, is FDA approved for single-agent use among relapsed… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)